Peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1ñ) is a protein that in humans is encoded by the PPARGC1A gene. PPARGC1A is also known as human accelerated region 20 (HAR20). It may, therefore, have played a key role in differentiating humans from apes.
PGC-1ñ is the master regulator of mitochondrial biogenesis. PGC-1ñ is also the primary regulator of liver gluconeogenesis, inducing increased gene expression for gluconeogenesis.
PGC-1ñ is a gene that contains two promoters, and has 4 alternative splicings. PGC-1ñ is a transcriptional coactivator that regulates the genes involved in energy metabolism. It is the master regulator of mitochondrial biogenesis. This protein interacts with the nuclear receptor PPAR-ó, which permits the interaction of this protein with multiple transcription factors. This protein can interact with, and regulate the activity of, cAMP response element-binding protein (CREB) and nuclear respiratory factors (NRFs) . PGC-1ñ provides a direct link between external physiological stimuli and the regulation of mitochondrial biogenesis, and is a major factor causing slow-twitch rather than fast-twitch muscle fiber types.
Endurance exercise has been shown to activate the PGC-1ñ gene in human skeletal muscle. Exercise-induced PGC-1ñ in skeletal muscle increases autophagy and unfolded protein response.
PGC-1ñ protein may also be involved in controlling blood pressure, regulating cellular cholesterol homeostasis, and the development of obesity.
PGC-1ñ is thought to be a master integrator of external signals. It is known to be activated by a host of factors, including:
PGC-1ñ has been shown to exert positive feedback circuits on some of its upstream regulators:
Akt and calcineurin are both activators of NF-kappa-B (p65). Through their activation, PGC-1ñ seems to activate NF-kappa-B. Increased activity of NF-kappa-B in muscle has recently been demonstrated following induction of PGC-1ñ. The finding seems to be controversial. Other groups found that PGC-1s inhibit NF-kappa-B activity. The effect was demonstrated for PGC-1 alpha and beta.
PGC-1ñ has also been shown to drive NAD biosynthesis to play a large role in renal protection in acute kidney injury.
PPARGC1A has been implicated as a potential therapy for Parkinson's disease conferring protective effects on mitochondrial metabolism.
Moreover, brain-specific isoforms of PGC-1alpha have recently been identified which are likely to play a role in other neurodegenerative disorders such as Huntington's disease and amyotrophic lateral sclerosis.
Massage therapy appears to increase the amount of PGC-1ñ, which leads to the production of new mitochondria.
PGC-1ñ and beta has furthermore been implicated in polarization to anti-inflammatory M2 macrophages by interaction with PPAR-ó with upstream activation of STAT6. An independent study confirmed the effect of PGC-1 on polarisation of macrophages towards M2 via STAT6/PPAR gamma and furthermore demonstrated that PGC-1 inhibits proinflammatory cytokine production.
PGC-1ñ has been recently proposed to be responsible for ò-aminoisobutyric acid secretion by exercising muscles. The effect of ò-aminoisobutyric acid in white fat includes the activation of thermogenic genes that prompt the browning of white adipose tissue and the consequent increase of background metabolism. Hence, the ò-aminoisobutyric acid could act as a messenger molecule of PGC-1ñ and explain the effects of PGC-1ñ increase in other tissues such as white fat.
PGC-1ñ increases BNP expression by coactivating Estrogen-related receptor alpha (ERRñ) and / or AP1. Subsequently, BNP induces a chemokine cocktail in muscle fibers and activates macrophages in a local paracrine manner, which can then contribute to enhancing the repair and regeneration potential of trained muscles.
Most studies reporting effects of PGC-1ñ on physiological functions have used mouse models in which the PGC-1ñ gene is either knocked out or overexpressed from conception. However, some of the proposed effects of PGC-1ñ have been questioned by studies using inducible knockout technology to remove the PGC-1ñ gene only in adult mice. For example, two independent studies have shown that adult expression of PGC-1ñ is not required for improved mitochondrial function after exercise training. This suggests that some of the reported effects of PGC-1ñ are likely to occur only in the developmental stage.
In the metabolic disorder of combined malonic and methylmalonic aciduria (CMAMMA) due to ACSF3 deficiency, there is a massively increased expression of PGC-1ñ, which is consistent with upregulated beta oxidation.
PPARGC1A has been shown to interact with:
ERRñ and PGC-1ñ are coactivators of both glucokinase (GK) and SIRT3, binding to an ERRE element in the GK and SIRT3 promoters.